UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...

Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Ajertil, A., Jirari Rim, M’Benga. L.-J.K. and El Quessar, A. (2025) Severe and Rare Cerebrovascular Involvement in Systemic Lupus Erythematosus: Case Report and Literature Review. Open Access Library ...

A literature review reports peer-reviewed studies associating prenatal and childhood pesticide exposure to measurable ...

Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly ...

UnsplashA landmark study has revealed that gluten sensitivity, which affects approximately 10 per cent of the global population, is not ...

Down syndrome affects around one in 640 children born in the US every year, and is the most common genetic cause of intellectual disability... | Cell And Molecular Biology ...

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...

Background Since the discovery of adaptive immunity and its ability to react to virtually any molecular structure, the concept of autoimmunity, historically ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.